TYNDALL JOSEPH A. 4
4 · Axogen, Inc. · Filed May 23, 2025
Insider Transaction Report
Form 4
Axogen, Inc.AXGN
TYNDALL JOSEPH A.
Director
Transactions
- Exercise/Conversion
Common Stock
2025-05-22$6.30/sh+12,850$80,955→ 35,407 total - Exercise/Conversion
Stock Option (right to purchase)
2025-05-22$6.30/sh−12,850$80,955→ 7,586 totalExercise: $6.30Exp: 2033-09-01→ Common Stock (12,850 underlying) - Sale
Common Stock
2025-05-22$11.20/sh−12,850$143,920→ 22,557 total - Sale
Common Stock
2025-05-22$11.20/sh−7,212$80,774→ 15,345 total
Footnotes (3)
- [F1]The price reported in Column 4 is a weighted average price. These shares of common stock were sold in multiple transactions at prices ranging from $11.15 to $11.31, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F2]The price reported in Column 4 is a weighted average price. These shares of common stock were sold in multiple transactions at prices ranging from $11.15 to $11.29, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]Options vested on the first anniversary of the grant date, which was September 1, 2023.